Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx: From Bone To Brain, Capitulation Creates A Free Option On The Neuro Pipeline
Ultragenyx is rated BUY with a $55 price target, offering 145% implied upside after a sharp post-trial selloff. RARE's commercial base, anchored by Crysvita and Dojolvi, provides a robust revenue safety net, with 2025 guidance above consensus and 20% projected annual growth. Key pipeline catalysts include GTX-102 Phase 3 data (Angelman's, H2 2025), GSDIa BLA submission, and Sanfilippo Syndrome Type A BLA resubmission, all with high success probabilities.
Ultragenyx Pharmaceutical Inc. (RARE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
RARE Rises on Completion of Rolling Submission for AAV Gene Therapy
Ultragenyx jumps after completing rolling BLA submission to the FDA for DTX401, an AAV gene therapy that could become the first approved treatment for GSDIa.
Ultragenyx (RARE) Moves 15.5% Higher: Will This Strength Last?
Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint
Ultragenyx and Mereo BioPharma shares fall as phase III Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta miss primary endpoints.
Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y
RARE's Q3 loss widens and revenues miss estimates, despite year-over-year sales growth of key rare disease drugs.
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2025 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. ( RARE ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Joshua Higa - Director of Investor Relations & Corporate Communications Emil Kakkis - Founder, President, CEO & Director Erik Harris - Executive VP & Chief Commercial Officer Howard Horn - Executive VP of Corporate Strategy & CFO Eric Crombez - Chief Medical Officer & Executive VP Conference Call Participants Huidong Wang - Barclays Bank PLC, Research Division Maurice Raycroft - Jefferies LLC, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Tazeen Ahmad - BofA Securities, Research Division Maxwell Skor - Morgan Stanley, Research Division Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Will Soghikian - Leerink Partners LLC, Research Division Joyce Chang Robbins - JPMorgan Chase & Co, Research Division Steve Scala - TD Cowen, Research Division Mehdi Goudarzi - Truist Securities, Inc., Research Division Mitchell Kapoor - H.C.
Here's What Key Metrics Tell Us About Ultragenyx (RARE) Q3 Earnings
The headline numbers for Ultragenyx (RARE) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should Know
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
